Can Mounjaro be prescribed for a patient with a previous history of Pancreatitis

Patients with a prior history of pancreatitis should generally avoid Mounjaro (tirzepatide) due to the potential risk of pancreatitis recurrence. Although direct causality between tirzepatide and pancreatitis has not been definitively established, there is a recognized association of incretin-based therapies, including GLP-1 receptor agonists and dual agonists like tirzepatide, with a small increased risk of pancreatitis, especially in susceptible individuals.

UK clinical guidelines advise caution or avoidance of GLP-1 receptor agonists in patients with a history of pancreatitis NICE CKS,NICE CKS. This is grounded in safety considerations given the lack of conclusive evidence that these agents do not provoke recurrent pancreatitis.

Recent trial data and meta-analyses report pancreatitis incidence with tirzepatide at approximately 0.2–0.3%, which is low and comparable to placebo rates; however, this does not exclude risk, particularly in patients with prior pancreatitis Thiriveedi et al. 2026. While no definitive causality is proven, the risk remains a clinical concern.

Therefore, the use of Mounjaro in patients with a history of pancreatitis several years ago requires a careful individualized risk-benefit assessment. If considered necessary, such patients should be closely monitored for any signs of pancreatitis during treatment, and alternative diabetes or obesity therapies without this risk should be preferentially considered.

In summary, although tirzepatide demonstrates superior glycemic and weight loss benefits, current UK advice and cautious interpretation of clinical evidence suggest avoiding its use in patients with prior pancreatitis due to the potential risk of pancreatitis recurrence NICE CKS,NICE CKS, Thiriveedi et al. 2026.